BillionToOne, Inc.

NASDAQ:BLLN

Medical - Diagnostics & Research

Healthcare
$91.54 +0.84%

+$0.84 today

Market cap
$4.37B
Beta
0.90
P/E (TTM)
182.6
EPS (TTM)
$0.55
52W Low $61.96High $138.70

Volume 1.44M

Average 0.59M

BLLN Interest Expense

Cost of servicing the company's debt during the period.

BillionToOne, Inc.NASDAQ: BLLN

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense declines year over year

Q2 FY2026 interest expense of $8K fell 75.0% year over year, ahead of the -92.4% change in trailing-twelve-month interest expense. Sequentially, it fell 20.0% from the prior quarter.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Interest expense increased in 0 of the last 2 fiscal years.
  • FY2025 was the lowest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly growth of -75.0% holds above the trailing-twelve-month pace of -92.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$8K-20.0% QoQ
Last fiscal yearDec 2025
$95K-96.0% YoY
LTMJun 2026
$41K-92.4% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-75.0%——
1 year-96.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
95K USD
Year-over-year change
-96.0%
2-year CAGR
-83.0%

Interest Expense vs competitors

How BLLN compares with its peers on the latest reported figures

  • BLLN's LTM Jun 2026 interest expense of $41K is the 7th highest of the 9 companies compared; the peer median is $2.78M.
  • Its year-over-year change of -92.4% is the 7th highest of 8, against a peer median of -0.5%.
  • Interest expense amounts to 0.0% of revenue for BLLN, versus a peer median of 0.4%.
BLLN Competitors Peer median
Interest Expense for BLLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MYGNMyriad Genetics, Inc.LTM Mar 2026$13.8M +345.2%+48.6%1.7%
NTRANatera, Inc.LTM Jun 2026$9.97M +54.2%-24.1%0.4%
GHGuardant Health, Inc.LTM Sep 2026$5.22M +55.2%+14.8%0.4%
WGSGeneDx Holdings Corp.LTM Jun 2026$2.98M -0.5%-7.5%0.7%
NEONeoGenomics, Inc.LTM Jun 2026$2.58M -55.6%-20.9%0.3%
FLGTFulgent Genetics, Inc.LTM Mar 2026$196K -17.6%-58.0%0.1%
BLLNBillionToOne, Inc.LTM Jun 2026$41K -92.4%—0.0%
GRALGRAIL, Inc.LTM Jun 2026$0 ——0.0%
VCYTVeracyte, Inc.LTM Jun 2026$0 -100.0%—0.0%
Peer median (excluding BLLN) $2.78M-0.5%-14.2%0.4%

Competitors are the stored peer set for BLLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue71.73M152.58M305.11M
Cost of Revenue54.42M71.67M96.65M
Gross Profit17.31M80.92M208.46M
Gross Margin24.1%53.0%68.3%
Research & Development22.41M36.6M49.38M
Selling, General & Admin64.39M91.47M143.05M
Operating Expenses86.8M128.06M192.44M
Depreciation & Amortization6.46M11.69M11.91M
EBITDA(72.94M)(27.47M)19.76M
EBITDA Margin-101.7%-18.0%6.5%
Operating Income(69.5M)(47.15M)16.02M
Operating Margin-96.9%-30.9%5.3%
Interest Income3.46M5.82M7.75M
Interest Expense3.27M2.39M95K
Other Income / Expenses(13.18M)5.61M(8.26M)
Income Before Tax(82.67M)(41.54M)7.76M
Pre-Tax Margin-115.3%-27.2%2.5%
Income Tax Expense9K29K305K
Net Income(82.68M)(41.57M)7.45M
Net Margin-115.3%-27.2%2.4%
EPS (Basic)(1.85)(0.93)0.06
EPS (Diluted)(1.85)(0.93)0.06
Weighted Avg Shares44.72M44.72M45.8M
Weighted Avg Shares (Diluted)44.72M44.72M45.8M

BillionToOne, Inc.

NASDAQ:BLLN

Intrinsic Alpha fair value

Locked

Current Price

$91.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.